Chloramphinaramine

# Chloramphinaramine ## Overview - **Classification**: Novel broad-spectrum antibiotic - **Mechanism**: Inhibits bacterial protein synthesis by reversibly binding to the 50S ribosomal subunit. ## Primary Indications 1. **Complicated Skin and Soft Tissue Infections (cSSTI)** - Infections unresponsive to first-line agents. 2. **Nosocomial Pneumonia (NP)** - Including ventilator-associated pneumonia (VAP). 3. **MDR Gram-positive bacterial infections** - Specific indications for multi-drug resistant strains. ## Adult Dosing ### Standard Dosing **Complicated Skin and Soft Tissue Infections (cSSTI)** - **Dose**: **500 mg** - **Frequency**: Every 12 hours - **Route**: Intravenous infusion over 60 minutes - **Duration**: 7 to 14 days, depending on infection severity **Nosocomial Pneumonia (NP)** - **Dose**: **750 mg** - **Frequency**: Every 12 hours - **Route**: Intravenous infusion over 60 minutes - **Duration**: 10 to 14 days ### Dose Adjustments - **Renal Impairment**: - CrCl 30-50 mL/min: Reduce dose by 25% (e.g., 375 mg for cSSTI) - CrCl <30 mL/min: Reduce dose by 50% (e.g., 250 mg for cSSTI) - Hemodialysis: Administer dose after dialysis session. - **Hepatic Impairment**: No specific dose adjustment recommended for mild-moderate impairment. - **Elderly Patients**: No specific dose adjustment solely based on age; consider renal function. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **5 mg/kg** - **Frequency**: Every 24 hours - **Maximum**: **5 mg/kg/dose** - **Special Notes**: Due to immature renal function, monitor drug levels closely. ### Infants (1-12 months) - **Dose**: **7.5 mg/kg** - **Frequency**: Every 12 hours - **Maximum**: **250 mg/dose** ### Children (1-12 years) - **Dose**: **10 mg/kg** - **Frequency**: Every 12 hours - **Maximum**: **500 mg/dose** ### Adolescents (13-18 years) - **Dose**: Follow adult dosing recommendations. - **Maximum**: Adult dose of **500 mg** or **750 mg**, depending on indication. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to chloramphinaramine or any component. - **Absolute**: Concurrent use with potent CYP3A4 inducers (e.g., rifampin). - **Relative**: History of bone marrow suppression. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, Diarrhea, Headache - **Common (1-10%)**: Vomiting, Rash, Dizziness, Elevated LFTs - **Serious but Rare**: Bone marrow suppression (aplastic anemia, leukopenia, thrombocytopenia), Gray baby syndrome (in neonates), Peripheral neuropathy, Optic neuritis. ### Key Drug Interactions - **CYP3A4 Inhibitors**: May increase chloramphinaramine levels; monitor for toxicity. - **CYP3A4 Inducers**: May decrease chloramphinaramine levels; co-administration is contraindicated. - **Anticoagulants (warfarin)**: May potentiate anticoagulant effect; monitor INR/PT closely. - **Myelosuppressive agents**: Increased risk of bone marrow suppression; avoid concurrent use if possible. ## Monitoring & Follow-up - **Before Treatment**: Complete Blood Count (CBC) with differential, Liver Function Tests (LFTs), Renal Function Tests (RFTs). - **During Treatment**: Weekly CBC with differential, LFTs, and RFTs (more frequently if abnormalities occur). - **Clinical Signs**: Monitor for signs of bone marrow suppression (fever, unusual bleeding/bruising, fatigue), neuropathy (tingling, numbness). ## Clinical Pearls - 💡 **Tip 1**: Consider therapeutic drug monitoring (TDM) in patients with renal impairment, hepatic dysfunction, or neonates. - 💡 **Tip 2**: Administer infusions over at least 60 minutes to minimize infusion-related reactions. - 💡 **Tip 3**: Counsel patients on symptoms of myelosuppression and neuropathy, and to report these immediately. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.